OpenAI Launches GeneBench-Pro: Expert-Level Genomics Benchmark for Frontier AI

OpenAI released GeneBench-Pro on June 30, 2026 — a 129-problem expert computational biology benchmark using synthetically generated problems with deterministic grading [1]. GPT-5.6 Sol scores 31.5% with Pro mode enabled, compared to below 5% for GPT-5, and OpenAI predicts the benchmark may saturate by year-end [1]. The release coincides with GPT-5.6's US-only access restriction, prompting debate about whether frontier AI for science will remain accessible to the global research community [3][4]. No other major lab has published GeneBench-Pro scores as of the launch date.

If AI can reliably solve expert genomics problems at a few dollars each versus the $4,000–8,000 a human expert charges per problem [1], the economic case for AI-assisted computational biology is direct. The access restriction debate carries practical stakes: researchers and institutions outside the US may be excluded from the highest-capability models precisely when those models become scientifically relevant.

OpenAI released GeneBench-Pro on June 30, 2026, framing it as a research-level evaluation of whether AI systems can handle the multi-step expert reasoning that characterizes graduate-level computational biology.[1] The 129 problems are synthetically generated with fully known causal structures, enabling deterministic grading and preventing models from exploiting analytic shortcuts or ambiguous answer paths that have weakened other long-horizon biology benchmarks.[1] Each question is designed to require sequential reasoning: models must first identify and correct domain-specific data artifacts — ambient RNA contamination, low-mappability genomic contacts, label inversions, and plate effects — before addressing the primary biological question.[2] Problem types span at least ten distinct subfields, including lncRNA dependency analysis, cis-multivariable Mendelian randomization, carrier screening, single-cell RNA-seq eQTL modeling, and ancient selection inference.[2]

GPT-5.6 Sol achieves a 31.5% pass rate with Pro mode enabled, compared to below 5% for GPT-5 — approximately a six-fold increase in successful problem-solving.[1] OpenAI also reports an efficiency result: GPT-5.6 Sol at its highest reasoning level solves nearly six times as many problems as GPT-5.2 while consuming approximately two-thirds the tokens, suggesting test-time compute scaling is delivering large returns in scientific reasoning.[1] Open-source models underperform GPT models on GeneBench-Pro by a wider margin than on coding benchmarks, which OpenAI interprets as evidence of broader scientific reasoning capability beyond code generation alone.[1] OpenAI itself states: "At the current pace, this benchmark may be saturated by the end of the year."

The economic framing in OpenAI's announcement is direct: human experts require roughly 20–40 hours per problem at approximately $200 per hour, while AI inference costs only several dollars per problem.[1] The concurrent release of GPT-5.6 — restricted to US users at launch[3] — has sharpened a parallel debate about scientific access. Commentator @ollobrains argues that frontier closed-weight AI now carries a sovereign kill switch: major pharmaceutical companies will retain access through institutional channels, but independent researchers and non-US institutions cannot rely on restricted models for genomics work and should shift toward open-weight alternatives.[4][5][6] The same author notes that developer adoption was already moving toward Chinese and open-weight models on price and latency grounds before any policy restriction was imposed.[7]

GeneBench-Pro's credibility faces a structural challenge common to lab-created benchmarks: OpenAI both designed the evaluation and currently leads it, with no independent reproduction of the methodology as of the launch date. Community leaderboards at LLM Stats and BenchLM.ai have begun tracking results[8][9], and Time magazine covered OpenAI's broader FrontierScience evaluation program[10], reflecting external attention — but independent validation of the benchmark's design choices, including whether synthetic problem generation captures real-world genomics failure modes, remains pending.